Who are Placebo Upadacitinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OPA-15406.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-upadacitinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo Upadacitinib — Competitive Intelligence Brief

Placebo Upadacitinib (Placebo Upadacitinib) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK1 inhibitor. Area: Immunology.

marketed JAK1 inhibitor JAK1 (Janus kinase 1) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo Upadacitinib (Placebo Upadacitinib) — AbbVie. Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo Upadacitinib TARGET	Placebo Upadacitinib	AbbVie	marketed	JAK1 inhibitor	JAK1 (Janus kinase 1)
OPA-15406	OPA-15406	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	JAK1 inhibitor	JAK1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK1 inhibitor class)

AbbVie · 2 drugs in this class
Arcutis Biotherapeutics, Inc. · 1 drug in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo Upadacitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-upadacitinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab